Real World Data of Cabozantinib in Patients with Hepatocellular Carcinoma: Focusing on Dose Setting and Modification

Overview

Journal Cancer Med

Specialty Oncology

Date 2024 Sep 24

PMID 39315523

Authors

Hironao Okubo

Hitoshi Ando

Shunsuke Nakamura

Yusuke Takasaki

Koichi Ito

Yuka Fukuo

Kenichi Ikejima

Hiroyuki Isayama

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate the outcomes of cabozantinib in patients with unresectable hepatocellular carcinoma (uHCC), focusing on dose setting and modification.

Methods: We retrospectively analyzed 34 Japanese patients who received cabozantinib for uHCC. Trough concentrations (C) of cabozantinib were also measured weekly for 6 weeks in the 18 patients.

Results: Sixteen patients received ≥40 mg (high-dose group), and 18 patients received 20 mg (low-dose group). Dose escalations were performed in 27.8% of the patients in the low-dose group. Although median duration of the first dose reduction or interruption in the low-dose group was twice that in the high-dose group (28 vs. 14 days, p < 0.001), there were no significant differences in the relative dose intensity (RDI) during 6 weeks, progression free survival (PFS), and overall survival (p = 0.162, p = 0.950, p = 0.817, respectively) between the two groups. Patients who received RDI during 6 weeks ≥33.4% showed a trend toward longer median PFS (p = 0.054). Each serum aldolase value during the 6 weeks was significantly correlated with the C at any point (r = 0.500, p < 0.001). In multivariate analyses, aldolase ≥8.7 U/L within 2 weeks was significantly associated with the very early dose reduction or interruption (odds ratio 20.0, p = 0.002).

Conclusions: An initial dose of 20 mg cabozantinib could be a safe option in Japanese patients. The serum aldolase value could be useful for making appropriate dose modifications of cabozantinib.

Citing Articles

Real world data of cabozantinib in patients with hepatocellular carcinoma: Focusing on dose setting and modification.

Okubo H, Ando H, Nakamura S, Takasaki Y, Ito K, Fukuo Y Cancer Med. 2024; 13(18):e70222.

PMID: 39315523 PMC: 11420626. DOI: 10.1002/cam4.70222.

References

Yakes F, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P . Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011; 10(12):2298-308. DOI: 10.1158/1535-7163.MCT-11-0264. View

Okubo H, Ando H, Ishizuka K, Morishige J, Ikejima K, Shiina S . Impact of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of lenvatinib in patients with hepatocellular carcinoma. J Pharmacol Sci. 2021; 148(1):6-13. DOI: 10.1016/j.jphs.2021.08.011. View

Abou-Alfa G, Meyer T, Cheng A, El-Khoueiry A, Rimassa L, Ryoo B . Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018; 379(1):54-63. PMC: 7523244. DOI: 10.1056/NEJMoa1717002. View

Kanzaki H, Ogasawara S, Okubo T, Itokawa N, Yoshino R, Fujimoto K . Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective Analysis. Drugs Real World Outcomes. 2023; 10(4):513-520. PMC: 10730490. DOI: 10.1007/s40801-023-00379-x. View

Okubo H, Ando H, Takasaki Y, Nakadera E, Fukuo Y, Shiina S . Impact of Cabozantinib Exposure on Proteinuria and Muscle Toxicity in Patients with Unresectable Hepatocellular Carcinoma. Pharmaceuticals (Basel). 2022; 15(12). PMC: 9783864. DOI: 10.3390/ph15121460. View

Yasu T, Gando Y, Nishijima R, Ikuta R, Suzuki M, Shirota M . Plasma Cabozantinib Level Measurement in Patients with Renal Cell and Hepatocellular Carcinomas Using a Simple HPLC-UV Method Suitable for Clinical Application. Curr Oncol. 2023; 30(5):4871-4879. PMC: 10217095. DOI: 10.3390/curroncol30050367. View

Yamanaka T, Takemura K, Hayashida M, Suyama K, Urakami S, Miura Y . Cabozantinib-induced serum creatine kinase elevation and rhabdomyolysis: a retrospective case series. Cancer Chemother Pharmacol. 2023; 92(3):235-240. DOI: 10.1007/s00280-023-04557-0. View

Choueiri T, Escudier B, Powles T, Tannir N, Mainwaring P, Rini B . Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016; 17(7):917-927. DOI: 10.1016/S1470-2045(16)30107-3. View

Lacy S, Miles D, Nguyen L . Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib. Clin Pharmacokinet. 2016; 56(5):477-491. DOI: 10.1007/s40262-016-0461-9. View

10.

Chan S, Ryoo B, Mo F, Chan L, Cheon J, Li L . Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment. J Hepatol. 2024; 81(2):258-264. DOI: 10.1016/j.jhep.2024.03.033. View

11.

Tomonari T, Tani J, Ogawa C, Deguchi A, Senoh T, Moriya A . Multicenter retrospective study of initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma. Hepatol Res. 2022; 53(2):172-178. DOI: 10.1111/hepr.13845. View

12.

Okubo H, Ando H, Nakamura S, Takasaki Y, Ito K, Fukuo Y . Real world data of cabozantinib in patients with hepatocellular carcinoma: Focusing on dose setting and modification. Cancer Med. 2024; 13(18):e70222. PMC: 11420626. DOI: 10.1002/cam4.70222. View

13.

Storandt M, Gile J, Palmer M, Zemla T, Ahn D, Bekaii-Saab T . Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma. Cancers (Basel). 2022; 14(21). PMC: 9657200. DOI: 10.3390/cancers14215173. View

14.

Nokihara H, Nishio M, Yamamoto N, Fujiwara Y, Horinouchi H, Kanda S . Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2019; 20(3):e317-e328. DOI: 10.1016/j.cllc.2018.12.018. View

15.

Kudo M, Tsuchiya K, Kato N, Hagihara A, Numata K, Aikata H . Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study. J Gastroenterol. 2021; 56(2):181-190. PMC: 7862203. DOI: 10.1007/s00535-020-01753-0. View

16.

Brancaccio P, Lippi G, Maffulli N . Biochemical markers of muscular damage. Clin Chem Lab Med. 2010; 48(6):757-67. DOI: 10.1515/CCLM.2010.179. View

17.

Fitzmaurice C, Allen C, Barber R, Barregard L, Bhutta Z, Brenner H . Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2016; 3(4):524-548. PMC: 6103527. DOI: 10.1001/jamaoncol.2016.5688. View

18.

Castellano D, Maroto J, Benzaghou F, Taguieva N, Nguyen L, Clary D . Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care. Cancer Treat Rev. 2020; 89:102062. DOI: 10.1016/j.ctrv.2020.102062. View

19.

Jing Z, Okubo H, Morishige J, Xu P, Hasan N, Nagata N . Lenvatinib causes reduced expression of carnitine/organic cation transporter 2 and carnitine deficiency in the skeletal muscle of rats. Toxicol Lett. 2022; 366:17-25. DOI: 10.1016/j.toxlet.2022.06.012. View

20.

Bang Y, Lee C, Yoo C, Chon H, Hong M, Kang B . Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis. Ther Adv Med Oncol. 2022; 14:17588359221097934. PMC: 9118905. DOI: 10.1177/17588359221097934. View